Prevention of postasphyxia electroretinal dysfunction with a pyridoxal hydrazone.
The newborn retina is particularly sensitive and frequently subjected to peroxidative stresses that result in visual sequelae. We compared two iron chelators, deferoxamine and a newer compound, pyridoxal isonicotinoyl hydrazone (PIH), in protecting the retina of newborn pigs (1-3 d old) from asphyxia-reoxygenation insults. Animals were treated IV with either saline, deferoxamine 15.2 mumol/kg (10 mg/kg) or PIH 34.8 mumol/kg (10 mg/kg); n = 10 in each treatment group. Scotopic and photopic electroretinograms (ERG) were recorded before and 40 min after drug treatment as well as 45 min following a 5-min period of asphyxia by interrupting ventilation. In separate animals the indices of peroxidation, malondialdehyde (MDA: TBARS) and hydroperoxides, were measured in retina at the same times. In saline-treated animals, there was a marked increase in MDA and hydroperoxide concentrations in the retina following the asphyxia-reoxygenation period. This was associated with a decrease in the a- (photoreceptor generated) and b-wave (generated by Müller and bipolar cells) amplitudes measured under photopic (cone-mediated response) and scotopic (rod-mediated response) conditions, and an increase in their implicit times. PIH and deferoxamine prevented the postasphyxial increase in MDA and hydroperoxides. However, only PIH prevented the postasphyxial changes in a- and b-wave amplitudes and implicit times, whereas deferoxamine markedly altered the preasphyxial ERG and provided only partial postasphyxial protection simply to the retinal outer segment. Our findings indicate that the iron chelator PIH effectively inhibits peroxidation and retinal electrophysiological alterations secondary to asphyxia-reoxygenation-induced oxidative stresses to newborn animals, whereas deferoxamine adversely affects retinal function; hence, PIH may be a preferred alternative to deferoxamine.
Bhattacharya
M
M
Department of Physiology, McGill University, Montreal, Canada.
Ponka
P
P
Hardy
P
P
Hanna
N
N
Varma
D R
DR
Lachapelle
P
P
Chemtob
S
S
D000818:Animals; D000831:Animals, Newborn; D001238:Asphyxia Neonatorum / Q000150:complications / Q000188:drug therapy*; D003676:Deferoxamine / Q000627:therapeutic use; D004195:Disease Models, Animal; D004596:Electroretinography; D006801:Humans; D006861:Hydrogen Peroxide / Q000378:metabolism; D007231:Infant, Newborn; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D007538:Isoniazid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008315:Malondialdehyde / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects*; D010545:Peroxides / Q000378:metabolism; D011730:Pyridoxal / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012160:Retina / Q000187:drug effects* / Q000378:metabolism; D013552:Swine; D014786:Vision Disorders / Q000517:prevention & control*
D007502:Iron Chelating Agents; D010545:Peroxides; D011730:Pyridoxal; D008315:Malondialdehyde; C021079:pyridoxal isonicotinoyl hydrazone; D006861:Hydrogen Peroxide; D003676:Deferoxamine; D007538:Isoniazid